Business
Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) --
About this update from Avalon Globocare Corp.
[{"type":"text","content":"Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection\nFREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit www.dna4addiction.com. Avalon owns a 40% equity interest in LSM. The opioid abuse epidemic continues to devastate communities across America, representing a significant public health crisis. According to the Centers for Disease Control and Prevention (CDC), the United States has experienced a dramatic rise in drug overdose deaths. In 2022, opioids were involved in over 75% of the nearly 107,000 drug overdose fatalities. From 2020 to 2021 alone, opioid-involved death rates increased by more than 15%, while synthetic opioid death rates increased by over 22%. DNA4Addiction offers a convenient home testing kit for customers to collect a DNA sample and send it for analysis. Researchers have identified 15 genetic markers linked to opioid dependence. These markers influence susceptibility to developing opioid dependence through factors such as neurotransmitter activity, reward pathways, and substance sensitivity. The test analyzes these markers to assess genetic predisposition to opioid dependence. For example, variations in neurotransmitter function, like dopamine, can affect the brain’s reward system and related behaviors. The results categorize individuals into High Risk, Moderate Risk, or Reduced Risk levels based on specific genetic variations. While this test is not a diagnosis, it provides valuable insights for proactive health management. \"Having a genetic predisposition to opioid dependence can significantly impact an individual’s susceptibility to excessive opioid use,\" stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. \"Though it is not a diagnosis or guarantee, genetic factors play a crucial role in shaping one’s response to opioids, influencing tolerance, drug reaction, and the likelihood of developing dependence. Recognizing this ...